Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2012

01.02.2012 | 2011 SSAT Plenary Presentation

Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm

verfasst von: Christy E. Cauley, Joshua A. Waters, Ryan P. Dumas, Juliana E. Meyer, Mohammad A. Al-Haddad, John M. DeWitt, Keith D. Lillemoe, C. Max Schmidt

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Limited data are available regarding the natural history of patients undergoing primary surveillance for intraductal papillary mucinous neoplasm (IPMN). We hypothesize that symptoms, radiologic characteristics, and cytopathology will predict cancer risk during surveillance.

Methods

Between March 2002 and March 2010, 522 patients were diagnosed with IPMN at a single, high-volume institution. Low versus high oncologic risk was stratified prospectively. Patients with under 3 months of surveillance were excluded.

Results

Two hundred ninety-two patients underwent primary surveillance for IPMN. Two hundred forty-four (84%) were classified as low-risk IPMN. Mean surveillance duration was 35 (4–99) months. Thirty (12%) patients initially stratified as low-risk developed a new indication for pancreatic resection. Only 28 underwent resection, and pathologic tissue analysis revealed 27 (96%) low-grade IPMN and one (4%) high-grade dysplastic IPMN. Overall, two (1%) patients initially determined to be low-risk developed invasive cancer. Forty-eight (16%) patients stratified as high-risk IPMN were initially managed nonoperatively. Of the 13 (27%) high-risk patients that died during follow-up, two (15%) died from pancreatic cancer.

Conclusions

Progression to pancreatic cancer during surveillance for low-risk IPMN was rare. Current indications for resection did not forecast malignancy. Poor operative candidates with high-risk IPMN progressed to invasive cancer more commonly, though a substantial portion succumbed to non-IPMN-related death.
Literatur
1.
Zurück zum Zitat Sohn TA, Y.C., Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD., Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg, 2001. 234(3): p. 313–21 Sohn TA, Y.C., Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD., Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg, 2001. 234(3): p. 313–21
2.
Zurück zum Zitat Tanaka, M., et al., International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology, 2006. 6(1–2): p. 17–32.PubMedCrossRef Tanaka, M., et al., International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology, 2006. 6(1–2): p. 17–32.PubMedCrossRef
3.
Zurück zum Zitat Gourgiotis, S., M.P. Ridolfini, and S. Germanos, Intraductal papillary mucinous neoplasms of the pancreas. European Journal of Surgical Oncology (EJSO), 2007. 33(6): p. 678–684.CrossRef Gourgiotis, S., M.P. Ridolfini, and S. Germanos, Intraductal papillary mucinous neoplasms of the pancreas. European Journal of Surgical Oncology (EJSO), 2007. 33(6): p. 678–684.CrossRef
4.
Zurück zum Zitat Hruban, R.H.M.T., Kyoichi MD, PhD; Klimstra, David S MD; Adsay, N Volkan MD; Albores-Saavedra, Jorge MD; Biankin, Andrew V MBBS, PhD; Biankin, Sandra A MBBS; Compton, Carolyn MD, PhD; Fukushima, Noriyoshi MD, PhD; Furukawa, Toru MD, PhD; Goggins, Michael MD; Kato, Yo MD, PhD; Kloppel, Gunter MD; Longnecker, Daniel S MD; Luttges, Jutta MD; Maitra, Anirban MBBS; Offerhaus, G Johan A MD; Shimizu, Michio MD, PhD; Yonezawa, Suguru MD, PhD, An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. The American Journal of Surgical Pathology, 2004. 28(8): p. 977–987. Hruban, R.H.M.T., Kyoichi MD, PhD; Klimstra, David S MD; Adsay, N Volkan MD; Albores-Saavedra, Jorge MD; Biankin, Andrew V MBBS, PhD; Biankin, Sandra A MBBS; Compton, Carolyn MD, PhD; Fukushima, Noriyoshi MD, PhD; Furukawa, Toru MD, PhD; Goggins, Michael MD; Kato, Yo MD, PhD; Kloppel, Gunter MD; Longnecker, Daniel S MD; Luttges, Jutta MD; Maitra, Anirban MBBS; Offerhaus, G Johan A MD; Shimizu, Michio MD, PhD; Yonezawa, Suguru MD, PhD, An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. The American Journal of Surgical Pathology, 2004. 28(8): p. 977–987.
5.
Zurück zum Zitat Longnecker DS, A.G., Hruban RH, Kloppel G, Intraductal papillary-mucinous neoplasms of the pancreas, in World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System:, A.L. Hamilton SR, Editor. 2000, Lyon, IARC Press. p. 237–241 Longnecker DS, A.G., Hruban RH, Kloppel G, Intraductal papillary-mucinous neoplasms of the pancreas, in World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System:, A.L. Hamilton SR, Editor. 2000, Lyon, IARC Press. p. 237–241
6.
Zurück zum Zitat Sho, M., et al., Pattern of Recurrence after Resection for Intraductal Papillary Mucinous Tumors of the Pancreas. World Journal of Surgery, 1998. 22(8): p. 874–878.PubMedCrossRef Sho, M., et al., Pattern of Recurrence after Resection for Intraductal Papillary Mucinous Tumors of the Pancreas. World Journal of Surgery, 1998. 22(8): p. 874–878.PubMedCrossRef
7.
Zurück zum Zitat Sawai, Y., Yamao K, Bhatia V, Chiba T, N. Mizuno, A. Sawaki, K. Takahashi, M. Tajika, Y. Shimizu, Y. Yatabe, A. Yanagisawa, Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy, 2010. 42(12): p. 1077–1084. Sawai, Y., Yamao K, Bhatia V, Chiba T, N. Mizuno, A. Sawaki, K. Takahashi, M. Tajika, Y. Shimizu, Y. Yatabe, A. Yanagisawa, Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. Endoscopy, 2010. 42(12): p. 1077–1084.
8.
Zurück zum Zitat D'Angelica M, B.M., Suriawinata AA, Klimstra D, Conlon KC., Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg, 2004. 239(3): p. 400–8. D'Angelica M, B.M., Suriawinata AA, Klimstra D, Conlon KC., Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg, 2004. 239(3): p. 400–8.
9.
Zurück zum Zitat Spinelli KS, F.T., Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA., Cystic pancreatic neoplasms: observe or operate. Ann Surg, 2004. 239(5): p. 651–7. Spinelli KS, F.T., Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA., Cystic pancreatic neoplasms: observe or operate. Ann Surg, 2004. 239(5): p. 651–7.
10.
Zurück zum Zitat Pelaez-Luna, M., et al., Do Consensus Indications for Resection in Branch Duct Intraductal Papillary Mucinous Neoplasm Predict Malignancy[quest] A Study of 147 Patients. Am J Gastroenterol, 2007. 102(8): p. 1759–1764.PubMedCrossRef Pelaez-Luna, M., et al., Do Consensus Indications for Resection in Branch Duct Intraductal Papillary Mucinous Neoplasm Predict Malignancy[quest] A Study of 147 Patients. Am J Gastroenterol, 2007. 102(8): p. 1759–1764.PubMedCrossRef
11.
Zurück zum Zitat Raut, C., et al., Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival. Annals of Surgical Oncology, 2006. 13(4): p. 582–594.PubMedCrossRef Raut, C., et al., Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival. Annals of Surgical Oncology, 2006. 13(4): p. 582–594.PubMedCrossRef
12.
Zurück zum Zitat Farnell, M.B., Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Journal of Gastrointestinal Surgery, 2008. 12(3): p. 414–6.PubMedCrossRef Farnell, M.B., Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Journal of Gastrointestinal Surgery, 2008. 12(3): p. 414–6.PubMedCrossRef
13.
Zurück zum Zitat Wiesenauer, C.A., et al., Preoperative Predictors of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasms. Arch Surg, 2003. 138(6): p. 610–618.PubMedCrossRef Wiesenauer, C.A., et al., Preoperative Predictors of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasms. Arch Surg, 2003. 138(6): p. 610–618.PubMedCrossRef
14.
Zurück zum Zitat Schmidt CM, W.P., Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD., Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg, 2007. 246(4): p. 644–51. Schmidt CM, W.P., Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD., Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg, 2007. 246(4): p. 644–51.
15.
Zurück zum Zitat Waters, J., et al., CT vs MRCP: Optimal Classification of IPMN Type and Extent. Journal of Gastrointestinal Surgery, 2008. 12(1): p. 101–109.PubMedCrossRef Waters, J., et al., CT vs MRCP: Optimal Classification of IPMN Type and Extent. Journal of Gastrointestinal Surgery, 2008. 12(1): p. 101–109.PubMedCrossRef
16.
Zurück zum Zitat Salvia R, F.-d.C.C., Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL, Main duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and longterm survival following resection. . Ann Surg, 2004. 239: p. 678–687 Salvia R, F.-d.C.C., Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL, Main duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and longterm survival following resection. . Ann Surg, 2004. 239: p. 678–687
17.
Zurück zum Zitat Waters, J.A. and C.M. Schmidt, Intraductal Papillary Mucinous Neoplasm--When to Resect? Advances in Surgery, 2008. 42: p. 87–108.PubMedCrossRef Waters, J.A. and C.M. Schmidt, Intraductal Papillary Mucinous Neoplasm--When to Resect? Advances in Surgery, 2008. 42: p. 87–108.PubMedCrossRef
18.
Zurück zum Zitat Bassi, C., et al., Natural History of Intraductal Papillary Mucinous Neoplasms (IPMN): Current Evidence and Implications for Management. Journal of Gastrointestinal Surgery, 2008. 12(4): p. 645–650.PubMedCrossRef Bassi, C., et al., Natural History of Intraductal Papillary Mucinous Neoplasms (IPMN): Current Evidence and Implications for Management. Journal of Gastrointestinal Surgery, 2008. 12(4): p. 645–650.PubMedCrossRef
19.
Zurück zum Zitat Rodriguez, J.R., et al., Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. Gastroenterology, 2007. 133(1): p. 72–79.PubMedCrossRef Rodriguez, J.R., et al., Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. Gastroenterology, 2007. 133(1): p. 72–79.PubMedCrossRef
20.
Zurück zum Zitat Salvia, R., et al., Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut, 2007. 56(8): p. 1086–1090.PubMedCrossRef Salvia, R., et al., Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut, 2007. 56(8): p. 1086–1090.PubMedCrossRef
21.
Zurück zum Zitat Sarr, M.G., et al., Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. Journal of Gastrointestinal Surgery, 2003. 7(3): p. 417–28.PubMedCrossRef Sarr, M.G., et al., Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. Journal of Gastrointestinal Surgery, 2003. 7(3): p. 417–28.PubMedCrossRef
22.
Zurück zum Zitat Schmidt, C.M. and K.D. Lillemoe, IPMN—Controversies in an “Epidemic”. Journal of Surgical Oncology, 2006. 94(2): p. 91–93.PubMedCrossRef Schmidt, C.M. and K.D. Lillemoe, IPMN—Controversies in an “Epidemic”. Journal of Surgical Oncology, 2006. 94(2): p. 91–93.PubMedCrossRef
23.
Zurück zum Zitat Sohn, T.A., et al., Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Annals of Surgery, 2004. 239(6): p. 788–97; discussion 797–9PubMedCrossRef Sohn, T.A., et al., Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Annals of Surgery, 2004. 239(6): p. 788–97; discussion 797–9PubMedCrossRef
24.
Zurück zum Zitat Bernard, P., et al., Intraductal Papillary-Mucinous Tumors of the Pancreas: Predictive Criteria of Malignancy According to Pathological Examination of 53 Cases. Arch Surg, 2002. 137(11): p. 1274–1278.PubMedCrossRef Bernard, P., et al., Intraductal Papillary-Mucinous Tumors of the Pancreas: Predictive Criteria of Malignancy According to Pathological Examination of 53 Cases. Arch Surg, 2002. 137(11): p. 1274–1278.PubMedCrossRef
25.
Zurück zum Zitat Sugiyama, M. and Y. Atomi, Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol, 1999. 94(2): p. 470–473.PubMedCrossRef Sugiyama, M. and Y. Atomi, Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol, 1999. 94(2): p. 470–473.PubMedCrossRef
26.
Zurück zum Zitat White, R., et al., Fate of the Remnant Pancreas after Resection of Noninvasive Intraductal Papillary Mucinous Neoplasm. Journal of the American College of Surgeons, 2007. 204(5): p. 987–993.PubMedCrossRef White, R., et al., Fate of the Remnant Pancreas after Resection of Noninvasive Intraductal Papillary Mucinous Neoplasm. Journal of the American College of Surgeons, 2007. 204(5): p. 987–993.PubMedCrossRef
27.
Zurück zum Zitat Maker, A., et al., Pancreatic Cyst Fluid and Serum Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgical Oncology, 2011. 18(1): p. 199–206.PubMedCrossRef Maker, A., et al., Pancreatic Cyst Fluid and Serum Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgical Oncology, 2011. 18(1): p. 199–206.PubMedCrossRef
Metadaten
Titel
Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm
verfasst von
Christy E. Cauley
Joshua A. Waters
Ryan P. Dumas
Juliana E. Meyer
Mohammad A. Al-Haddad
John M. DeWitt
Keith D. Lillemoe
C. Max Schmidt
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2012
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1757-6

Weitere Artikel der Ausgabe 2/2012

Journal of Gastrointestinal Surgery 2/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.